1.Surgical release ofcongenital trigger thumb.
Ik Dong KIM ; Poong Taek KIM ; Byung Chul PARK ; Young Gu LYU ; Il Hyung PARK ; Koo Hee LEE
The Journal of the Korean Orthopaedic Association 1991;26(3):825-831
No abstract available.
Trigger Finger Disorder*
2.A case of granulosa cell tumor in pregnancy.
Hyun Chul CHO ; Sang Hee LEE ; Poong Gu LEE ; Jeong Gyu SHIN ; Won Jun CHOI ; Soon Ae LEE ; Jong Hak LEE ; Won Young PAIK
Korean Journal of Obstetrics and Gynecology 2002;45(7):1259-1262
Granulosa cell tumors of the ovary are rare, and account for 2 to 3% of ovarian tumors. Granulosa cell tumors are discovered often in perimenopausal or postmenopausal women but 10 to 26% are found in the reproductive age group. The tumors associated with pregnancy are infrequent. In this study, we present a case of granulosa cell tumor of left ovary at pregnancy.
Female
;
Granulosa Cell Tumor*
;
Granulosa Cells*
;
Humans
;
Ovary
;
Pregnancy*
3.The Efficacy of High-dose Melphalan with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Jae Lyun LEE ; Sung Bae KIM ; Gyeong Won LEE ; Min Hee RYU ; Eun Kyoung KIM ; Shin KIM ; Woo Kun KIM ; Jung Shin LEE ; Sang Hee KIM ; Cheol Won SUH
Yonsei Medical Journal 2003;44(5):800-810
Although high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (ASCT) is widely accepted as an effective and safe consolidation therapy for multiple myeloma (MM), few reports on its efficacy are available in Korea. We present the results of a prospective phase II study, involving 33 patients with MM treated with HDT with ASCT. The treatment consisted of 4 courses of VAD (vincristine, adriamycin, dexamethasone) induction, peripheral blood stem cell collection, and high-dose melphalan with stem cell infusion. The overall response rate was 93%, with 45% of patients having complete responses. The toxicity was predictable and tolerable. With a median follow-up of 27.6 months, the 2-year event free survival rate was 43%. At the time of writing, the median overall survival duration had not been reached with 2-year survival and projected 3-year survival rates of 81% and 74%, respectively. The overall survival was significantly better than that of the historical control patients (N=82) treated with conventional chemotherapy at our institution. The results suggest that HDT with ASCT is a valuable first or second-line treatment for patients with MM.
Adult
;
Aged
;
Female
;
Human
;
Male
;
Melphalan/*therapeutic use
;
Middle Aged
;
Multiple Myeloma/mortality/pathology/*therapy
;
Neoplasm Staging
;
*Peripheral Blood Stem Cell Transplantation
;
Prognosis
;
Prospective Studies
;
Survival Rate
;
Transplantation, Autologous